AGM
OREX

Alpine Global Management’s Orexigen Therapeutics, Inc. OREX Stock Holding History

Alpine Global Management’s Portfolio OREX Stock Details OREX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-13,877
Closed -$60K – 248
2016
Q2 		$60K Buy
+13,877
New +$62.7K 0.03% 160
2015
Q3 		– Sell
-32
Closed -$2K – 1229
2015
Q2 		$2K Buy
+32
New +$1.91K ﹤0.01% 1132

Other funds holding OREX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Alpine Global Management's OREX Position: Q3 2016 in Review

Alpine Global Management sold out of Orexigen Therapeutics, Inc. (OREX) in Q3 2016, closing a stake of 13,877 shares — an estimated $60K sold.

Alpine Global Management first reported a position in OREX in Q2 2015 and held it in 2 quarters. The position peaked at $60K in Q2 2016. 55 funds tracked by Wall St. Rank hold OREX as of Q3 2016.

  • Alpine Global Management reported no remaining Orexigen Therapeutics, Inc. position as of Q3 2016 after selling out during the quarter.
  • Alpine Global Management sold 13,877 Orexigen Therapeutics, Inc. shares in Q3 2016, an estimated $60K.
  • Alpine Global Management first reported a position in Orexigen Therapeutics, Inc. in Q2 2015 and held it in 2 quarters.
  • Alpine Global Management's Orexigen Therapeutics, Inc. position peaked at $60K in Q2 2016.
  • 55 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q3 2016.

Based on Alpine Global Management's 13F filing for Q3 2016, filed 15 Nov 2016.